Anebulo Pharmaceuticals, Inc.
ANEB
$1.05
-$0.02-1.87%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.11% | 15.12% | 3.44% | -7.51% | -26.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.72% | 10.94% | 11.01% | -13.00% | -24.92% |
| Operating Income | -13.72% | -10.94% | -11.01% | 13.00% | 24.92% |
| Income Before Tax | -4.06% | -6.57% | -3.45% | 17.73% | 26.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.06% | -6.57% | -3.45% | 17.73% | 26.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.06% | -6.57% | -3.45% | 17.73% | 26.92% |
| EBIT | -13.72% | -10.94% | -11.01% | 13.00% | 24.92% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 33.17% | 23.15% | 15.84% | 26.36% | 28.91% |
| Normalized Basic EPS | 33.20% | 23.11% | 15.85% | 26.38% | 28.90% |
| EPS Diluted | 33.17% | 23.15% | 15.84% | 26.36% | 28.91% |
| Normalized Diluted EPS | 33.20% | 23.11% | 15.85% | 26.38% | 28.90% |
| Average Basic Shares Outstanding | 56.19% | 45.45% | 31.20% | 16.87% | 2.46% |
| Average Diluted Shares Outstanding | 56.19% | 45.45% | 31.20% | 16.87% | 2.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |